"The FDA has approved glucarpidase (marketed as Voraxaze) to lower toxic levels of methotrexate related to kidney failure. Cancer patients may develop kidney failure when treated with high doses of methotrexate. In a study of 22 patients receiving glucarpidase, 10 patients had methotrexate levels fall below a critical level within 15 minutes and stay low for 8 days. The drug eliminated 95% of methotrexate in all patients."
This should be a resourceful drug for our patients; especially those who receive intrathecall/IV MTX and get kidney injury where we often have to do dialysis due to the toxic levels; so potentially saving patients from dialysis and it's complications.
- ► 2018 (27)
- ► 2017 (52)
- ► 2016 (45)
- ► 2015 (63)
- ► 2014 (95)
- ► 2013 (133)
- TOPIC DISCUSSION: The BAMBI tale of the Kidney
- IMMUNOSUPPRESSION IN THE ELDERLY: WHATS THE BEST I...
- CLINICAL CASE 50: Answers and Summary
- HISTORY LESSON: Story Behind Central Pontine Myeli...
- New drug labels for kidney disease patients -- wha...
- Are dialysis patients at an increased risk of GI b...
- IN THE NEWS: LUNAR TRIAL
- FDA Approves Glucarpidase to Reduce Toxic Levels o...
- IN THE NEWS: Soluble FLT-1 and ANCA... Not just pr...
- ANAGRAMS: Secondary causes of ANCA disease
- eAJKD PODCAST: APOL1 and the Kidney
- Nephrology Crosswords: Interventional Nephrology
- TOPIC DISCUSSION: Atypical ANCA and it's significa...
- eAJKD: Anemia story
- eAJKD: Interest in Nephrology declining
- IN THE NEWS: Face Transplantation
- Detective Nephron: Next venture
- eAJKD: Hypertension, hypokalemia and MPGN
- CLINICAL CASE 49: Answers and Discussion
- IN THE NEWS: Which glomerular disease is highest r...
- Consult Rounds: Renal disease in Retroperitoneal F...
- Kidney Transplantation Induction Quiz Answers
- ▼ January (23)
- ► 2011 (370)
- ► 2010 (461)